Patents by Inventor David T. Puerta
David T. Puerta has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10414735Abstract: The present teachings relate to hydroxypyrimidinone derivatives of Formula IV, pharmaceutical compositions thereof, and methods of using such compounds to treat bacterial infections.Type: GrantFiled: November 9, 2016Date of Patent: September 17, 2019Assignee: FORGE THERAPEUTICS, INC.Inventors: Min Teng, Baskar Nammalwar, Konstantin Taganov, David T. Puerta
-
Publication number: 20190106398Abstract: There are provided inter alia metalloenzyme inhibitors, such as inhibitors of influenza A RNA dependent RNA polymerase PA subunit endonuclease, and methods of synthesis and use of the same.Type: ApplicationFiled: September 7, 2018Publication date: April 11, 2019Inventors: Seth M. Cohen, Cy V. Credille, David T. Puerta
-
Publication number: 20180327365Abstract: The present teachings relate to hydroxypyridinone and hydroxypyrimidinone derivatives, pharmaceutical compositions thereof, and methods of using such compounds to treat bacterial infections.Type: ApplicationFiled: November 9, 2016Publication date: November 15, 2018Inventors: Min TENG, Baskar NAMMALWAR, Konstantin TAGANOV, David T. PUERTA
-
Publication number: 20180319761Abstract: The present teachings relate to pyrone derivatives, pharmaceutical compositions thereof, and methods of using such compounds to treat bacterial infections.Type: ApplicationFiled: November 9, 2016Publication date: November 8, 2018Inventors: Min TENG, Baskar NAMMALWAR, Konstantin TAGANOV, David T. PUERTA
-
Publication number: 20170088532Abstract: Provided herein, inter alia, are compounds and methods for treating infectious diseases. The compounds provided herein are, inter alia, useful for the treatment of bacterial infections. The compounds provided herein are, inter alia, useful inhibitors of metalloproteins, e.g. UDP-3-O—(R-3-hydroxymyristoyl)-N-acetylglucosamine deacetylase (LpxC).Type: ApplicationFiled: June 3, 2016Publication date: March 30, 2017Inventors: Seth M. Cohen, David T. Puerta, Christian Perez
-
Patent number: 9138398Abstract: Compositions are disclosed comprising novel fluorinated cationic alcohols in a cosmetically acceptable vehicle. The fluorinated compounds alter a surface property of the hair to provide hair conditioning, for example. In embodiments, the compounds have improved water solubility and deposition properties.Type: GrantFiled: February 12, 2013Date of Patent: September 22, 2015Assignee: Living Proof, Inc.Inventors: David T. Puerta, Lorna Nagamoottoo-Casse, Kevin T. Love
-
Patent number: 8404221Abstract: Compositions are disclosed comprising novel fluorinated cationic alcohols in a cosmetically acceptable vehicle. The fluorinated compounds alter a surface property of the hair to provide hair conditioning, for example. In embodiments, the compounds have improved water solubility and deposition properties.Type: GrantFiled: July 12, 2012Date of Patent: March 26, 2013Assignee: Living Proof, Inc.Inventors: David T. Puerta, Lorna Nagamoottoo-Casse, Kevin T. Love
-
Patent number: 8318945Abstract: The present invention relates to metalloprotein inhibitors comprising: a. an organic substituent and at least one zinc binding group (ZBG) covalently attached thereto; or b. a ZBG substituted by a side chain wherein the ZBG is of formula (I): wherein X is O or S and each R1, R2, R3, and R4 is individually hydrogen or an organic radical. The metalloprotein inhibitors are useful for preventing or treating a pathological disease, condition, or symptom that is associated with pathological metalloprotein activity and/or that is alleviated by inhibition of said activity.Type: GrantFiled: August 15, 2011Date of Patent: November 27, 2012Assignee: The Regents of the University of CaliforniaInventors: David T. Puerta, Seth M. Cohen, Jana A. Lewis
-
Publication number: 20120276036Abstract: Compositions are disclosed comprising novel fluorinated cationic alcohols in a cosmetically acceptable vehicle. The fluorinated compounds alter a surface property of the hair to provide hair conditioning, for example. In embodiments, the compounds have improved water solubility and deposition properties.Type: ApplicationFiled: July 12, 2012Publication date: November 1, 2012Applicant: LIVING PROOF, INC.Inventors: David T. Puerta, Lorna Nagamoottoo-Casse, Kevin T. Love
-
Patent number: 8242309Abstract: Compositions are disclosed comprising novel fluorinated cationic alcohols in a cosmetically acceptable vehicle. The fluorinated compounds alter a surface property of the hair to provide hair conditioning, for example. In embodiments, the compounds have improved water solubility and deposition properties.Type: GrantFiled: September 16, 2010Date of Patent: August 14, 2012Assignee: Living Proof, Inc.Inventors: David T. Puerta, Lorna Nagamoottoo-Casse, Kevin T. Love
-
Publication number: 20120041032Abstract: The present invention relates to metalloprotein inhibitors comprising: a. an organic substituent and at least one zinc binding group (ZBG) covalently attached thereto; or b. a ZBG substituted by a side chain wherein the ZBG is of formula (I): wherein X is O or S and each R1, R2, R3, and R4 is individually hydrogen or an organic radical. The metalloprotein inhibitors are useful for preventing or treating a pathological disease, condition, or symptom that is associated with pathological metalloprotein activity and/or that is alleviated by inhibition of said activity.Type: ApplicationFiled: August 15, 2011Publication date: February 16, 2012Applicant: The Regents of the University of California, San DiegoInventors: David T. Puerta, Seth M. Cohen, Jana A. Lewis
-
Patent number: 8008510Abstract: The present invention relates to metalloprotein inhibitors comprising: a. an organic substituent and at least one zinc binding group (ZBG) covalently attached thereto; or b. a ZBG substituted by a side chain wherein the ZBG is of formula (I): wherein X is O or S and each R1, R2, R3, and R4 is individually hydrogen or an organic radical. The metalloprotein inhibitors are useful for preventing or treating a pathological disease, condition, or symptom that is associated with pathological metalloprotein activity and/or that is alleviated by inhibition of said activity.Type: GrantFiled: March 12, 2010Date of Patent: August 30, 2011Assignee: The Regents of the University of CaliforniaInventors: David T. Puerta, Seth M. Cohen, Jana A. Lewis
-
Publication number: 20110070179Abstract: Compositions are disclosed comprising novel fluorinated cationic alcohols in a cosmetically acceptable vehicle. The fluorinated compounds alter a surface property of the hair to provide hair conditioning, for example. In embodiments, the compounds have improved water solubility and deposition properties.Type: ApplicationFiled: September 16, 2010Publication date: March 24, 2011Applicant: Living Proof, Inc.Inventors: David T. Puerta, Lorna Nagamoottoo-Casse, Kevin T. Love
-
Patent number: 7786316Abstract: The present invention relates to metalloprotein inhibitors comprising: a. an organic substituent and at least one zinc binding group (ZBG) covalently attached thereto; or b. a ZBG substituted by a side chain wherein the ZBG is of formula (I): wherein X is O or S and each R1, R2, R3, and R4 is individually hydrogen or an organic radical. The metalloprotein inhibitors are useful for preventing or treating a pathological disease, condition, or symptom that is associated with pathological metalloprotein activity and/or that is alleviated by inhibition of said activity.Type: GrantFiled: July 15, 2009Date of Patent: August 31, 2010Assignee: The Regents of The University of CaliforniaInventors: David T. Puerta, Seth M. Cohen, Jana A. Lewis
-
Publication number: 20100173952Abstract: The present invention relates to metalloprotein inhibitors comprising: a. an organic substituent and at least one zinc binding group (ZBG) covalently attached thereto; or b. a ZBG substituted by a side chain wherein the ZBG is of formula (I): wherein X is O or S and each R1, R2, R3, and R4 is individually hydrogen or an organic radical. The metalloprotein inhibitors are useful for preventing or treating a pathological disease, condition, or symptom that is associated with pathological metalloprotein activity and/or that is alleviated by inhibition of said activity.Type: ApplicationFiled: March 12, 2010Publication date: July 8, 2010Applicant: The Regents of The University of California Office of Technology TransferInventors: David T. Puerta, Seth M. Cohen, Jana A. Lewis
-
Patent number: 7705164Abstract: The present invention relates to metalloprotein inhibitors comprising: a. an organic substituent and at least one zinc binding group (ZBG) covalently attached thereto; or b. a ZBG substituted by a side chain wherein the ZBG is of formula (I): wherein X is O or S and each R1, R2, R3, and R4 is individually hydrogen or an organic radical. The metalloprotein inhibitors are useful for preventing or treating a pathological disease, condition, or symptom that is associated with pathological metalloprotein activity and/or that is alleviated by inhibition of said activity.Type: GrantFiled: April 28, 2005Date of Patent: April 27, 2010Assignee: The Regents of the University of CaliforniaInventors: David T. Puerta, Seth M. Cohen, Jana A. Lewis
-
Publication number: 20100098640Abstract: Provided herein are chelating agents and metal chelates that are useful in diagnostic and therapeutic applications. The uses of metal chelates provided herein include their use as contrast agents in medical imaging modalities, such as magnetic resonance imaging (MRI).Type: ApplicationFiled: June 20, 2006Publication date: April 22, 2010Inventors: Seth M. Cohen, David T. Puerta
-
Publication number: 20090286987Abstract: The present invention relates to metalloprotein inhibitors comprising: a. an organic substituent and at least one zinc binding group (ZBG) covalently attached thereto; or b. a ZBG substituted by a side chain wherein the ZBG is of formula (I): wherein X is O or S and each R1, R2, R3, and R4 is individually hydrogen or an organic radical. The metalloprotein inhibitors are useful for preventing or treating a pathological disease, condition, or symptom that is associated with pathological metalloprotein activity and/or that is alleviated by inhibition of said activity.Type: ApplicationFiled: July 15, 2009Publication date: November 19, 2009Applicant: Regents of the University of California, San Diego UCSD Technology Transfer OfficeInventors: David T. Puerta, Seth M. Cohen, Jana A. Lewis
-
Patent number: 7579486Abstract: The present invention relates to metalloprotein inhibitors comprising: a. an organic substituent and at least one zinc binding group (ZBG) covalently attached thereto; or b. a ZBG substituted by a side chain wherein the ZBG is of formula (I): wherein X is O or S and each R1, R2, R3, and R4 is individually hydrogen or an organic radical. The metalloprotein inhibitors are useful for preventing or treating a pathological disease, condition, or symptom that is associated with pathological metalloprotein activity and/or that is alleviated by inhibition of said activity.Type: GrantFiled: October 30, 2006Date of Patent: August 25, 2009Assignee: Regents of the University of California, San DiegoInventors: David T. Puerta, Seth M. Cohen, Jana A. Lewis
-
Publication number: 20080161362Abstract: The present invention relates to metalloprotein inhibitors comprising: a. an organic substituent and at least one zinc binding group (ZBG) covalently attached thereto; or b. a ZBG substituted by a side chain wherein the ZBG is of formula (I): wherein X is O or S and each R1, R2, R3, and R4 is individually hydrogen or an organic radical. The metalloprotein inhibitors are useful for preventing or treating a pathological disease, condition, or symptom that is associated with pathological metalloprotein activity and/or that is alleviated by inhibition of said activity.Type: ApplicationFiled: April 28, 2005Publication date: July 3, 2008Applicant: Regents of the University of California, San Diego UCSD Technology transfer officeInventors: David T. Puerta, Seth M. Cohen, Jana A. Lewis